

## **FASENRA® PEDIATRIC ORDER FORM**

FAX TO: 855.694.4656

## **PATIENT INFORMATION**

PATIENT NAME:	PHC	DNE:
DATE OF BIRTH: SEX:MF I	HEIGHT: WEIGHT	:
ALLERGIES:	PREFERRED CLI	NIC:
REFERRAL STATUS: NEW REFERRAL ORDE	ER CHANGE ORDER RENEW	AL
DIAGNOSIS & CLINICAL DOCUMEN	TATION	
J45.50 Severe persistent asthma, uncomplicated J45.51 Severe persistent asthma with (acute) exa J82.83 Eosinophilic Asthma J30.1 Polyarteritis with lung involvement [EGPA/	cerbation /Churg-Strauss]	
REQUIRE	D DOCUMENTATION	
Insurance List of Medications	Tried & Failed Therapies	Most Recent History & Physical
Lab results and/or Pulmonary Function Tests to support diagnosis	Blood Eosinophil Level	CBC CBC
MEDICATION ORDER		
FOR PEDIATRIC PATIENTS AGED 6 – 11 WEIGHING LESS THAN 35K	(G	
LOADING: Fasenra® (benralizumab) 10mg via subcut MAINTENANCE: Fasenra® (benralizumab) 10mg via		
*FOR PEDIATRIC PATIENTS AGED 6 – 11 WEIGHING GREATER THAN  LOADING: Fasenra® (benralizumab) 30mg via subcu  MAINTENANCE: Fasenra® (benralizumab) 30mg via	taneous injection every 4 weeks in	itial 3 doses
REFILL X 12 MONTHS UNLESS OTHERWISE NOTED	) HERE:	
Patient to be observed for 30 minutes following the first injection and then for 15 minutes follonn the event of an adverse reaction occurring in the infusion clinic, utilize the Immersiv Health		
PRESCRIBER INFORMATION		
	NPI #:	
EMAIL:		
ADDRESS (INCLUDE CITY, STATE, ZIP):  SUPERVISING		
PHYSICIAN:	CONTACT NAME:	
SIGNATURE:		DATE:
(NO STAMPS) SUBSTITUTION PERMITTED	DISPENSE AS WRITTEN	